Efficacy comparison of tenofovir and entecavir in HBeAg-positive chronic hepatitis B patients with high HBV DNA

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Shi, Hong ^a   Huang, Mingxing ^a   Lin, Guoli ^a   Li, Xiangyong ^a   Wu, Yuankai ^a   Jie, Yusheng ^a   Chong, Yutian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; GUANINE; TENOFOVIR;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; GENETICS; HEPATITIS B, CHRONIC; MIDDLE AGED; PATHOGENICITY; VIROLOGY; VIRUS LOAD;

ADULT; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; TENOFOVIR; VIRAL LOAD;

EID: 84962282163     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/6725073     Document Type: Article

References (32)

1. M. Safioleas, N. J. Lygidakis, and C. Monti, "Hepatitis B today, " Hepato-Gastroenterology, vol. 54, no. 74, pp. 545-548, 2007.
2. F.-S. Wang, J.-G. Fan, Z. Zhang, B. Gao, and H.-Y. Wang, "The global burden of liver disease: the major impact of China, " Hepatology, vol. 60, no. 6, pp. 2099-2108, 2015.
3. E. B. Keeffe, D. T. Dieterich, S.-H. B. Han et al. , "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update, " Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315-1341, 2008.
4. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al. , "Long-termtherapywith adefovir dipivoxil forHBeAg-negative chronic hepatitis B for up to 5 years, " Gastroenterology, vol. 131, no. 6, pp. 1743-1751, 2006.
5. Y.-F. Liaw, E. Gane, N. Leung et al. , "2-YearGLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B, " Gastroenterology, vol. 136, no. 2, pp. 486-495, 2009.
6. A. S. F. Lok and B. J. McMahon, "Chronic hepatitis B: update 2009, " Hepatology, vol. 50, no. 3, pp. 661-662, 2009.
7. Y.-F. Liaw, J.-H. Kao, T. Piratvisuth et al. , "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, "Hepatology International, vol. 6, no. 3, pp. 531-561, 2012.
8. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection, " Journal of Hepatology, vol. 57, no. 1, pp. 167-185, 2012.
9. M. Huang, Y. Jie, H. Shi et al. , "Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China, " International Journal of Clinical and Experimental Medicine, vol. 8, no. 1, pp. 666-673, 2015.
10. S.-K. Kim, D.-J. Kim, S.-H. Kim et al. , "Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis, " Diabetes Research and Clinical Practice, vol. 88, no. 1, pp. 111-116, 2010.
11. C.-J. Chen, H.-I. Yang, J. Su et al. , "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level, " The Journal of the American Medical Association, vol. 295, no. 1, pp. 65-73, 2006.
12. U. H. Iloeje, H.-I. Yang, J. Su, C.-L. Jen, S.-L. You, and C.-J. Chen, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, " Gastroenterology, vol. 130, no. 3, pp. 678-686, 2006.
13. U. H. Iloeje, H.-I. Yang, and C.-J. Chen, "Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?" Liver International, vol. 32, no. 9, pp. 1333-1341, 2012.
14. J. Gauthier, E. J. Bourne, M. W. Lutz et al. , "Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine, " The Journal of Infectious Diseases, vol. 180, no. 6, pp. 1757-1762, 1999.
15. C.-H. Chen, J.-H. Wang, S.-N. Lu et al. , "Characteristics of adefovir resistance in patients with or without lamivudineresistant hepatitis B virus treated with adefovir: a 4-year experience, " Liver International, vol. 31, no. 2, pp. 206-214, 2011.
16. T.-T. Chang, R. G. Gish, R. De Man et al. , "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, " The New England Journal of Medicine, vol. 354, no. 10, pp. 1001-1010, 2006.
17. P. Marcellin, E. J. Heathcote, M. Buti et al. , "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, " The New England Journal of Medicine, vol. 359, no. 23, pp. 2442-2455, 2008.
18. A. Batirel, E. Guclu, F. Arslan et al. , "Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: amulticenter real-life study, " International Journal of Infectious Diseases, vol. 28, pp. e153-e159, 2014.
19. B. Ceylan, C. Yardimci, M. Fincanci et al. , "Comparison of tenofovir and entecavir in patientswith chronicHBVinfection, " European Review forMedical and Pharmacological Sciences, vol. 17, no. 18, pp. 2467-2473, 2013.
20. L. Gao, H. N. Trinh, J. Li, and M. H. Nguyen, "Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA, " Alimentary Pharmacology &Therapeutics, vol. 39, no. 6, pp. 629-637, 2014.
21. P. Lampertico, M. Vigano, R. Soffredini et al. , "Entecavir monotherapy in 418 nuc-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment, " in Hepatology, p. 1043A, Wiley-Blackwell Commerce Place, Malden, Mass, USA, 2011.
22. E. Ridruejo, R. Adrover, D. Cocozzella et al. , "Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice, " International Journal of Clinical Practice, vol. 65, no. 8, pp. 866-870, 2011.
23. P. Lampertico, R. Soffredini, M. Vigano et al. , "2-Year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practive, " Hepatology, vol. 54, supplement 1, abstract 1433, 2011.
24. W. Ke, L. Liu, C. Zhang et al. , "Comparisonof efficacy andsafety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis, " PLoS ONE, vol. 9, no. 6, Article ID e98865, 2014.
25. S. R. Zuo, X. C. Zuo, C. J. Wang et al. , "A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection, " The Journal of Clinical Pharmacology, vol. 55, no. 3, pp. 288-297, 2015.
26. C.-J. Liu, P.-J. Chen, M.-Y. Lai et al. , "Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B, " Liver International, vol. 26, no. 8, pp. 949-955, 2006.
27. H. Dakin, C. Fidler, and C. Harper, "Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B, " Value in Health, vol. 13, no. 8, pp. 934-945, 2010.
28. E. J. Heathcote, P. Marcellin, M. Buti et al. , "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B, " Gastroenterology, vol. 140, no. 1, pp. 132-143, 2011.
29. N. Leung, C. Peng, J. Sollano et al. , "Entecavir (ETV) results in higherHBVDNAreduction versus adefovir (ADV) in antiviralna ive HBeAg(+) adults with high HBV DNA: week 96 results (EARLY Study), " Journal of Hepatology, vol. 48, pp. S373-S374, 2008.
30. M. R. Nelson, C. Katlama, J. S. Montaner et al. , "The safety of tenofovir disoproxil fumarate for the treatment ofHIVinfection in adults: the first 4 years, " AIDS, vol. 21, no. 10, pp. 1273-1281, 2007.
31. G. L. Wong, Y. K. Tse, V. W. Wong, T. C. Yip, K. K. Tsoi, and H. L. Chan, "Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53, 500 subjects, " Hepatology, vol. 62, no. 3, pp. 684-693, 2015.
32. N. B. Ha, K. Ku, N. B. Ha, K. T. Chaung, H. N. Trinh, and M. H. Nguyen, "Renal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy: a matched case-cohort study, " Journal of Clinical Gastroenterology, vol. 49, no. 10, pp. 873-877, 2015.